Korsana Biosciences Quarterly Cash Flow Statement
NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
33.92+0.41 (+1.22%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Korsana Biosciences free cash flow
In the quarter ended Jun 30, 2026, Korsana Biosciences generated -$1.4 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$1.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Korsana Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1.75M | -3.18M | -799.00K | -976.00K | -324.00K | -1.43M | 530.00K | -723.00K | -1.32M | -1.54M | -1.69M | 7.57M |
| Net Income growth (YoY) | — | — | -250.75% | — | — | — | — | -109.56% | — | — | — | — |
| Depreciation & Amortization | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Stock-Based Compensation | 51.00K | 58.00K | 95.00K | 118.00K | 114.00K | 114.00K | 122.00K | 138.00K | 184.00K | 181.00K | 103.00K | 159.00K |
| Change in Working Capital | 1.14M | 949.00K | -872.00K | 443.00K | 35.00K | 68.00K | -470.00K | 16.00K | -91.00K | -456.00K | 385.00K | -1.05M |
| Operating Cash Flow | -1.43M | -1.18M | -1.58M | -264.00K | -503.00K | -968.00K | 360.00K | -1.72M | -1.11M | -1.87M | -1.54M | -6.93M |
| Capital Expenditures | 0 | -66.00K | — | — | 0 | 0 | — | — | — | — | — | — |
| Investing Cash Flow | 0 | -66.00K | — | — | 0 | 0 | 0 | 0 | — | — | 0 | 10.40M |
| Financing Cash Flow | 0 | 825.00K | 251.00K | 1.83M | -130.00K | 1.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -1.43M | -417.00K | -1.33M | 1.56M | -633.00K | 407.00K | 360.00K | -1.72M | -1.11M | -1.88M | -1.54M | 3.47M |
| Free Cash Flow | -1.43M | -1.24M | -1.58M | -264.00K | -503.00K | -968.00K | 360.00K | -1.72M | -1.11M | -1.87M | -1.54M | -6.93M |
This table shows 12 quarterly periods of Korsana Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KRSA's reporting calendar. What is a cash flow statement?